Summary
UnitedHealth Group Inc. (UNH) announced on August 4, 2017, the appointment of two new independent directors to its Board of Directors: Dr. Valerie Montgomery Rice and Sir Andrew Witty. These appointments are effective immediately and aim to enhance the board's expertise and diversity, particularly in healthcare and global pharmaceutical leadership. Dr. Rice brings a strong background in academic medicine and women's health research, serving as President and Dean of the Morehouse School of Medicine. Sir Andrew Witty is a distinguished figure in the pharmaceutical industry, having previously served as CEO of GlaxoSmithKline. Their collective experience is expected to provide valuable insights and strategic guidance to UnitedHealth Group as it navigates the complex healthcare landscape. Both directors will receive standard compensation and indemnification as per the company's existing policies.
Key Highlights
- 1Appointment of two new independent directors: Dr. Valerie Montgomery Rice and Sir Andrew Witty.
- 2Dr. Rice's expertise includes academic medicine, women's health research, and leadership at Morehouse School of Medicine.
- 3Sir Andrew Witty brings extensive global pharmaceutical experience, including his tenure as CEO of GlaxoSmithKline.
- 4The appointments are intended to strengthen the Board's diverse skill set and leadership experience.
- 5New directors will be compensated according to the company's standard director compensation program.
- 6Standard indemnification agreements will be entered into with both new directors.